AskBio - AAV Gene Therapy Technology & Therapeutics
Ask Bio. AskBio is a leading, clinical-stage gene therapy company dedicated to developing AAV gene therapies for genetic and complex...
Read Askbio.com news digest here: view the latest Ask Bio articles and content updates right away or get to their most visited pages. Askbio.com belongs to a large group of moderately popular websites, with around 4.9K visitors from all over the world monthly. It seems that Ask Bio content is notably popular in USA, as 92.5% of all users (4.6K visits per month) come from this country. We haven’t detected security issues or inappropriate content on Askbio.com and thus you can safely use it. Askbio.com is hosted with Cloud Servers Cell 0001-0003 IAD3 (United States) and its basic language is English.
Content verdict: Safe
Website availability: Live
Language: English
Last check:
-
165
Visitors daily -
494
Pageviews daily -
4
Google PR -
605 855
Alexa rank
Best pages on Askbio.com
-
AskBio - AAV Gene Therapy Technology & Therapeutics
AskBio is a leading, clinical-stage gene therapy company dedicated to developing AAV gene therapies for genetic and complex disorders. Learn more about our gene therapy technology and current clinical...
-
Asklepios BioPharmaceutical, Inc.
Company Mission & Market Opportunities AskBio is engaged in the development of novel protein and intercellular based therapies through design of proprietary Biological Nano Particle (BNP) platform tec...
Askbio.com news digest
-
4 months
AskBio Announces Initiation of Phase 2 GenePHIT Trial in Congestive Heart Failur...
GenePHIT, which is now enrolling, will study AB-1002 in adults with NYHA Class III Heart Failure and non-ischemic cardiomyopathy1
Research Triangle Park, N.C.– January 5, 2024 – Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that it is initiating GenePHIT (Gene PHosphatase Inhibition... -
4 months
AskBio Phase Ib trial of AB-1005 gene therapy in patients with Parkinson’s disea...
AB-1005 (AAV2-GDNF), an investigational gene therapy for the treatment of Parkinson’s disease, was well tolerated with no attributed serious adverse events in all 11 patients at 18 months.
18-month assessment of all patients demonstrated feasibility of administration of AB-1005 to the putamen via one-time bilateral convection-enhanced delivery.... -
5 months
AskBio Announces First Patient Randomized in Phase 1 Trial of AB-1005 (AAV2-GDNF...
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels in the brain for the treatment of MSA-P
Phase 1 randomized, controlled trial to assess safety of AB-1005 delivered to the putamen in patients with MSA-P... -
6 months
AskBio Presents Preliminary Data from Phase 1 Trial of Gene Therapy for Congesti...
First-in-human trial of AB-1002 designed to establish safety and preliminary efficacy in patients with NYHA Class III Heart Failure
Heart failure is a leading cause of morbidity and mortality worldwide despite available therapies, and quality of life is poor [1]...
Domain history
| Web host: | Cloud Servers Cell 0001-0003 IAD3 |
| Registrar: | GoDaddy.com, LLC |
| Registrant: | Registration Private (Domains By Proxy, LLC) |
| Updated: | March 20, 2023 |
| Expires: | March 14, 2033 |
| Created: | March 14, 2004 |
Whois record
Safety scores
Trustworthiness
N/AChild safety
N/A
